Shorter‐term and longer‐term mortality prediction in the Australian Diabetes, Obesity and Lifestyle (<scp>AusDiab</scp>) study
Classical risk factors for total and CVD mortality remain important up to 20 years after their measurement. In unselected adult cohorts, longer-term follow-up (e.g. beyond 10 years) may not provide additional information on associations of risk factors with mortality beyond that obtained in shorter-term follow-up.
Authors
- Agus Salim (ORCID: https://orcid.org/0000-0003-3999-7701)
- Paul Zimmet (ORCID: https://orcid.org/0000-0003-0627-0776)
- Jonathan E. Shaw (ORCID: https://orcid.org/0000-0002-6187-2203)
- Dunya Tomic (ORCID: https://orcid.org/0000-0003-2471-2523)
- Elizabeth Barr (ORCID: https://orcid.org/0000-0003-4284-1716)
- Dianna J. Magliano (ORCID: https://orcid.org/0000-0002-6026-5065)
Institutions
- Baker Heart and Diabetes Institute (AU)
- The University of Melbourne (AU)
- Charles Darwin University (AU)
- Menzies School of Health Research (AU)
- Monash University (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1111/imj.70015
- Primary Topic
- Chronic Disease Management Strategies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pratt Foundation
- Jack Brockhoff Foundation
- Pfizer Australia
- Kidney Health Australia
- GlaxoSmithKline Australia
- Department of Health and Aged Care, Australian Government
- Novo Nordisk
- AstraZeneca Australia
- Sanofi Australia
- Roche Diagnostics
- Amgen Australia
- Novartis Australia
- Eli Lilly Australia
- MSD Australia
- National Health and Medical Research Council
- Cilag